Search results

Frequently asked questions about ANSTO for the community.

Australian Nuclear Science and Technology Organisation (ANSTO) is committed to protecting your personal information in accordance with the Privacy Act 1988 (Cth) (Privacy Act) and the Australian Privacy Principles.

The Medium Energy- X-ray Absorption Spectroscopy beamlines will provide access to XANES and EXAFS data from a bending magnet source, optimised for cutting-edge applications in biological, agricultural and environmental science in an energy range that is not currently available at the Australia Synchrotron.

ANSTO recently hosted a public Ask Us Anything event on nuclear medicine, sharing information on how we safely manufacture and distribute nuclear medicine across Australia each week to hundreds of hospitals and clinics.

The High Performance Macromolecular Crystallography beamline will enable the study of very small (sub-5 micrometre) or weakly diffracting crystals, providing a state-of-the-art high-throughput facility for researchers. MX3 will be able to study the structures of large proteins and protein complexes for virology, drug design and industrial applications via goniometer mounted crystals, in-tray screening, or via serial crystallography methods.

ANSTO provides eduroam services for partnering institutions in Australia and around the world.

ANSTO is a highly regulated organisation. Our governance system and processes provide critical guidance to effectively manage ANSTO’s activities. This section outlines the processes and systems that are in place to provide assurance to Government, our stakeholders and the community that we are working within our regulated and mandated requirements.

See details of previously published customer updates from our Health products team. 

The International Synchrotron Access Program (ISAP) is administered by the Australian Synchrotron and is designed to assist Australian-based synchrotron users to access overseas synchrotron related facilities.

ANSTO’s user office in Melbourne offers access to the Australian Synchrotron, a world-class research facility with over 4,000 user visits per year. ANSTO seeks collaboration and partnerships with research organisations, scientific users and commercial users.

The new facility will be built around a product line of ANSTO’s design – a new Technetium-99m generator – that will enable greater process automation than is possible with existing technology, leading to improvements in efficiency, quality and importantly the highest levels of production safety.

Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia

Ongoing media statements relating to nuclear medicine production.

Retrieving an Antarctic ice core more than a million years old presents challenges and opportunities.

The Australian Nuclear Science and Technology Organisation (ANSTO) has joined a team, lead by the US Department of Energy’s Pacific Northwest National Laboratory (PNNL), to install a high resolution monitoring system at ANSTO’s medical isotope production facility in Lucas Heights, Australia.

At ANSTO we understand that diverse teams produce better outcomes – and we value the merit that a diverse perspective can bring to the quality and outcomes of our work, and the way we get the job done.